Ontology highlight
ABSTRACT:
SUBMITTER: Lehraiki A
PROVIDER: S-EPMC4860830 | biostudies-other | 2015
REPOSITORIES: biostudies-other
Lehraiki Abdelali A Cerezo Michael M Rouaud Florian F Abbe Patricia P Allegra Marilyne M Kluza Jerome J Marchetti Philippe P Imbert Veronique V Cheli Yann Y Bertolotto Corine C Ballotti Robert R Rocchi Stéphane S
Cell discovery 20151027
Specific BRAFV600E inhibitors (BRAFi) are highly effective in the treatment of melanoma. However, acquired drug resistances invariably develop after the initial response. Therefore, the identification of new mechanisms of acquired resistance gives important clues towards the development of therapies that could elicit long lasting responses. Here we report that CD271 confers resistance to BRAFi in melanoma cells. The expression of CD271 is increased by BRAFi through a stimulation of tumor necrosi ...[more]